See more : PT Prodia Widyahusada Tbk (PRDA.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Reviva Pharmaceuticals Holdings, Inc. (RVPH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Reviva Pharmaceuticals Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Cielo Waste Solutions Corp. (CMC.V) Income Statement Analysis – Financial Results
- Forza X1, Inc. (FRZA) Income Statement Analysis – Financial Results
- Maxigen Biotech Inc. (1783.TW) Income Statement Analysis – Financial Results
- Glenmark Pharmaceuticals Limited (GLENMARK.NS) Income Statement Analysis – Financial Results
- PT Bank Mandiri (Persero) Tbk (BMRI.JK) Income Statement Analysis – Financial Results
Reviva Pharmaceuticals Holdings, Inc. (RVPH)
About Reviva Pharmaceuticals Holdings, Inc.
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 724.74K | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -724.74K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 31,419.82B | 18.95M | 4.85M | 295.15K | 195.74K | 946.30K |
| General & Administrative | 8,083.82B | 5.36M | 5.25M | 2.14M | 181.12K | 175.58K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8,083.82B | 5.36M | 5.25M | 2.14M | 181.12K | 175.58K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 39,503.64B | 24.31M | 10.10M | 2.43M | 376.86K | 1.12M |
| Cost & Expenses | 39.50M | 24.31M | 10.10M | 2.43M | 376.86K | 1.12M |
| Interest Income | 0.00 | 182.80K | 0.00 | 105.18K | 201.00 | 0.00 |
| Interest Expense | 0.00 | 182.80K | 2.41K | 1.45M | 469.37K | 0.00 |
| Depreciation & Amortization | 0.00 | 194.71K | 236.56K | 105.77K | 846.00 | 1.02K |
| EBITDA | -39,503.64B | -24.11M | -10.10M | -2.33M | -376.01K | -1.12M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -39,503.64B | -24.31M | -10.10M | -2.43M | -376.86K | -1.12M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 39,503.60B | -11.91K | 1.59M | -1.35M | -469.17K | -557.68K |
| Income Before Tax | -39.24M | -24.32M | -8.52M | -3.78M | -846.03K | -1.68M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -16.95B | 20.78K | 6.00K | 800.00 | 800.00 | 800.00 |
| Net Income | -39,260.84B | -24.34M | -8.52M | -3.78M | -846.83K | -1.68M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.65 | -1.25 | -0.58 | -1.24 | -0.31 | 0.00 |
| EPS Diluted | -1.65 | -1.25 | -0.58 | -1.24 | -0.31 | 0.00 |
| Weighted Avg Shares Out | 23.80M | 19.52M | 14.79M | 3.06M | 2.77M | 0.00 |
| Weighted Avg Shares Out (Dil) | 23.80M | 19.52M | 14.79M | 3.06M | 2.77M | 0.00 |
Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights
– 108 patients have completed 1-year of treatment in 1-year open-label extension (OLE) trial – – Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine's improvement on negative symptoms and other key symptom domains of schizophrenia – – Topline...
Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024
CUPERTINO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory...
Reviva to Participate in the UBS Global Healthcare Conference
CUPERTINO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory...
Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit
CUPERTINO, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory...
Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
CUPERTINO, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory...
Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules
CUPERTINO, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory...
Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension
- Patent covers brilaroxazine use for treating pulmonary hypertension (PH), pulmonary arterial hypertension (PAH) in any patients including treating PH in patients with chronic obstructive pulmonary disease (COPD) or sickle cell disease (SCD)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH
NEW YORK, NY / ACCESSWIRE / June 1, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Reviva Pharmaceuticals Holdings, Inc. ("Reviva" or the "Company") (NASDAQ:RVPH). Such investors are advised to contact Danielle Peyton at [email protected] or...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH
NEW YORK , May 30, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Reviva Pharmaceuticals Holdings, Inc. ("Reviva" or the "Company") (NASDAQ: RVPH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980,...
Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
CUPERTINO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and...
Source: https://incomestatements.info
Category: Stock Reports